Savara Inc: directors' dealings · United States · SEC (Form 4)

About Savara Inc

Savara Inc. is a U.S.-listed clinical-stage biopharmaceutical company trading on the NASDAQ Global Select Market in the United States under the ticker SVRA. For international equity investors, the investment case is highly focused: Savara is a rare respiratory disease specialist built around a single lead program rather than a broad multi-asset pipeline. The company’s core asset is MOLBREEVI, an inhaled biologic (molgramostim inhalation solution), which is being developed for autoimmune pulmonary alveolar proteinosis (autoimmune PAP), a rare, chronic, debilitating lung disease marked by abnormal surfactant accumulation in the alveoli. From a corporate history standpoint, Savara was incorporated in Delaware in December 1995. Its corporate headquarters is in Langhorne, Pennsylvania, and company disclosures indicate that a significant portion of employees work remotely. This relatively lean operating footprint is typical for a specialty biotech concentrating resources on clinical development, regulatory execution, and eventual commercialization readiness. Geographically, the business remains primarily U.S.-centered today, although the company has also been pursuing a European regulatory path, reflecting its ambition to address the disease in major developed markets. In competitive terms, Savara occupies a narrow but potentially attractive niche in precision respiratory medicine. Its strategy rests on a combination of late-stage clinical data, deep focus on rare pulmonary disease, and the possibility of becoming a first or only approved pharmaceutical option for autoimmune PAP, subject to regulatory success. The program has received multiple supportive designations, including Fast Track, Breakthrough Therapy, and Orphan Drug status in the United States, alongside comparable rare-disease recognitions in Europe and the UK. These designations are important because they may support development efficiency and underscore the unmet medical need, but they do not remove the substantial regulatory and launch risk inherent in a single-asset biotech. Recent company news has been heavily centered on the FDA review process for MOLBREEVI. After receiving a Refusal to File letter in May 2025, Savara resubmitted its Biologics License Application in December 2025; the FDA then formally filed the BLA and granted Priority Review in February 2026. In its first-quarter 2026 update, Savara said it held approximately $203 million in cash and short-term investments as of March 31, 2026, and had access to roughly an additional $150 million of non-dilutive capital contingent on FDA approval. The company has also been building commercial and diagnostic infrastructure around autoimmune PAP, including a U.S. diagnostic test launch and specialty-pharmacy arrangements, signaling preparation for a potential transition from development-stage biotech to commercial-stage respiratory therapeutics company.